Mepacrine Inhibits Matrix Metalloproteinases-1 (MMP-1) and MMP-9 Activation in Human Fibroblast-like Synoviocytes

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2330-2337

  Stuhlmeier, Karl M ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Gene regulation; Human fibroblast like synoviocytes; Matrix metalloproteinase; Mepacrine; Quinacrine; Transcription factor

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MEPACRINE; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATIC DISEASE; SYNOVIOCYTE; WESTERN BLOTTING;

CELLS, CULTURED; ELECTROPHORESIS; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; QUINACRINE; RNA, MESSENGER; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTOR AP-1;

EID: 0242693161     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Angel P, Karin M. Specific members of the Jun protein family regulate collagenase expression in response to various extracellular stimuli. Matrix 1992;1 Suppl:156-64.
2. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
3. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
4. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6.
5. Lochter A, Bissell MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999;107:128-36.
6. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-56.
7. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33.
8. Furcht LT, Skubitz AP, Fields GB. Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab Invest 1994;70:781-3.
9. Blavier L, Henriet P. Imren S, Declerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 1999;878:108-19.
10. Elliott S, Cawston T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging 2001;18:87-99.
11. Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - targetting gelatinase A activation. Inflamm Res 2001;50:183-6.
12. Katrib A, Tak PP, Bertouch JV, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology Oxford 2001;40:988-94.
13. Gordon JL, Drummond AH, Galloway WA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol 1993;11:S91-4.
14. Steffen C, Menzel J, Zeitlhofer J, Smolen J, Lanzer G. Experimental arthritis induced by granulocyte collagenase. Scand J Rheumatol 1980;9:179-86.
15. Nguyen Q, Mort JS, Roughley PJ. Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in human articular cartilage. J Clin Invest 1992;89:1189-97.
16. Lohmander LS, Lark MW, Dahlberg L, Walakovits LA, Roos H. Cartilage matrix metabolism in osteoarthritis: markers in synovial fluid, serum, and urine. Clin Biochem 1992;25:167-74.
17. Zafarullah M, Pelletier JP, Cloutier JM, Martel-Pelletier J. Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. J Rheumatol 1993;20:693-7.
18. Wolfe GC, MacNaul KL, Buechel FF, et al. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis Rheum 1993;36:1540-7.
19. Huebner JL, Otterness IG, Freund EM, Caterson B, Kraus VB. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum 1998;41:877-90.
20. Bluteau G, Conrozier T, Mathieu P, Vignon E, Herbage D, Mallein-Gerin F. Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta 2001;1526:147-58.
21. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-41.
22. 2. Biochem Pharmacol 1980;29:623-7.
23. 2 inhibitors quinacrine and 7, 7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts. J Pharmacol Exp Ther 1992;262:1161-7.
24. 2. Basic Res Cardiol 1997;92:17-24.
25. Ferrante A, Rowan-Kelly B, Seow WK, Thong YH. Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 1986;58:125-30.
26. Mikes PS, Polomski LL, Gee JB. Mepacrine impairs neutrophil response after acute lung injury in rats. Effects on neutrophil migration. Am Rev Respir Dis 1988;138:1464-70.
27. Al Khader A, Al Sulaiman M, Kishore PN, Morais C, Tariq M. Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats. Transplantation 1996;62:427-35.
28. 2 activity by chloroquine and mepacrine. J Pharm Pharmacol 1982;34:736-8.
29. Wallace DJ. Is there a role for quinacrine (atabrine) in the new millennium? Lupus 2000;9:81-2.
30. Wallace DJ. The use of quinacrine (atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989;18:282-96.
31. D'Cruz D. Antimalarial therapy: a panacea for mild lupus? Lupus 2001;10:148-51.
32. Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997;24:569-72.
33. Lipsker D, Piette JC, Cacoub P, Godeau P, Frances C. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995;190:257-8.
34. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000;9:92-5.
35. Matucci-Cerinic M, Marabini S, Jantsch S, Cagnoni M, Partsch G. Effects of capsaicin on the metabolism of rheumatoid arthritis synoviocytes in vitro. Ann Rheum Dis 1990;49:598-602.
36. Ozols J. Amino acid analysis. Methods Enzymol 1990;182:587-601.
37. Dyer RB, Herzog NK. Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. Biotechniques 1995;19:192-5.
38. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
39. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996;6:391-411.
40. Stuhlmeier KM, Csizmadia V, Cheng Q, Winkler H, Bach FH. Selective inhibition of E-selectin, ICAM-1 and VCAM in endothelial cells. Eur J Immunol 1994;24:2186-90.
41. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
42. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
43. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998;2:466-71.
44. Stuhlmeier KM. Effects of quinacrine on endothelial cell morphology and transcription factor-DNA interactions. Biochim Biophys Acta 2001;1524:57-65.
45. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-400.
46. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 1988;55:917-24.
47. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000;19:2056-68.
48. Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 2002;22:4952-64.
49. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999;18:188-97.
50. Rutberg SE, Saez E, Lo S, et al. Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters. Oncogene 1997;15:1337-46.
51. Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J 1991;10:3839-49.
52. 2 activation and induction of interleukin 1 beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998;30:357-66.
53. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.
54. Jeong JY, Jue DM. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997;158:4901-7.
55. Scaria PV, Craig JC, Shafer RH. Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers 1993;33:887-95.
56. Rivas L, Murza A, Sanchez-Cortes S, Garcia-Ramos JV. Interaction of antimalarial drug quinacrine with nucleic acids of variable sequence studied by spectroscopic methods. J Biomol Struct Dyn 2000;18:371-83.
57. Jerushalmy Z, Englender T, Shaklai M. Phorbol-myristate-acetate-induced platelet aggregation in the presence of inhibitors. Acta Haematol 1988;80:210-5.
58. Shen CY, Wang D, Chang ML, Hsu K. Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats. J Appl Physiol 1995;78:225-31.
59. 2 activity by chloroquine and mepacrine. J Pharm Pharmacol 1982;34:736-8.
60. Cussac D, Schaak S, Denis C, Paris H. Alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation. J Biol Chem 2002;277:19882-8.
61. von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P. Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus. Hautarzt 2000;51:82-5.
62. Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26:251-8.
63. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-9.